fosun international ltd. - SFOSF

SFOSF

Close Chg Chg %
2.44 0.28 11.29%

Pre-Market

2.71

+0.28 (11.29%)

Volume: 500.00

Last Updated:

Mar 25, 2026, 9:30 AM EDT

Company Overview: fosun international ltd. - SFOSF

SFOSF Key Data

Open

$2.71

Day Range

2.71 - 2.71

52 Week Range

1.62 - 3.50

Market Cap

$7.15B

Shares Outstanding

2.64B

Public Float

N/A

Beta

1.06

Rev. Per Employee

N/A

P/E Ratio

15.29

EPS

$0.18

Yield

166.12%

Dividend

$0.04

EX-DIVIDEND DATE

Jul 24, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

51.20

 

SFOSF Performance

1 Week
 
11.29%
 
1 Month
 
3.83%
 
3 Months
 
-13.97%
 
1 Year
 
50.56%
 
5 Years
 
N/A
 

SFOSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About fosun international ltd. - SFOSF

Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.

SFOSF At a Glance

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Building A
Shanghai, Shanghai 200233
Phone 86-21-3398-7870 Revenue 5.77B
Industry Pharmaceuticals: Major Net Income 468.89M
Sector Health Technology 2025 Sales Growth 1.553%
Fiscal Year-end 12 / 2026 Employees 40,603
View SEC Filings

SFOSF Valuation

P/E Current 15.293
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.175
Price to Sales Ratio 1.151
Price to Book Ratio 0.951
Price to Cash Flow Ratio 7.96
Enterprise Value to EBITDA 13.651
Enterprise Value to Sales 2.005
Total Debt to Enterprise Value 0.454

SFOSF Efficiency

Revenue/Employee 142,199.38
Income Per Employee 11,548.059
Receivables Turnover 3.577
Total Asset Turnover 0.346

SFOSF Liquidity

Current Ratio 0.929
Quick Ratio 0.757
Cash Ratio 0.422

SFOSF Profitability

Gross Margin 46.062
Operating Margin 6.082
Pretax Margin 7.681
Net Margin 8.121
Return on Assets 2.809
Return on Equity 6.972
Return on Total Capital 3.834
Return on Invested Capital 5.401

SFOSF Capital Structure

Total Debt to Total Equity 75.325
Total Debt to Total Capital 42.963
Total Debt to Total Assets 30.476
Long-Term Debt to Equity 30.596
Long-Term Debt to Total Capital 17.451
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fosun International Ltd. - SFOSF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
6.51B 5.82B 5.69B 5.77B
Sales Growth
+8.00% -10.53% -2.35% +1.55%
Cost of Goods Sold (COGS) incl D&A
3.62B 3.26B 3.18B 3.11B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
363.49M 440.18M 440.61M 496.93M
Depreciation
201.14M 230.15M 272.74M 299.19M
Amortization of Intangibles
145.76M 188.36M 144.33M 189.52M
COGS Growth
+10.45% -9.78% -2.66% -1.96%
Gross Income
2.89B 2.56B 2.51B 2.66B
Gross Income Growth
+5.08% -11.47% -1.97% +6.01%
Gross Profit Margin
+44.42% +43.95% +44.13% +46.06%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.40B 2.40B 2.11B 2.27B
Research & Development
581.26M 527.14M 444.46M 495.31M
Other SG&A
1.82B 1.88B 1.67B 1.78B
SGA Growth
+1.06% +0.11% -12.08% +7.41%
Other Operating Expense
24.86M 35.14M 32.25M 37.33M
Unusual Expense
400.58M 71.64M 20.57M 53.54M
EBIT after Unusual Expense
62.78M 47.49M 341.73M 297.63M
Non Operating Income/Expense
491.39M 297.00M 213.49M 326.96M
Non-Operating Interest Income
51.32M 59.97M 58.56M 49.82M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
147.38M 192.09M 204.31M 181.09M
Interest Expense Growth
+11.51% +30.34% +6.36% -11.36%
Gross Interest Expense
154.17M 199.03M 207.34M 184.18M
Interest Capitalized
6.80M 6.93M 3.03M 3.09M
Pretax Income
406.79M 152.39M 350.91M 443.49M
Pretax Income Growth
-38.48% -62.54% +130.26% +26.38%
Pretax Margin
+6.25% +2.62% +6.17% +7.68%
Income Tax
93.10M 52.15M 91.27M 120.20M
Income Tax - Current - Domestic
121.09M 74.69M 141.40M 145.48M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(27.99M) (22.54M) (50.13M) (25.28M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (148.28K)
-
Consolidated Net Income
586.22M 408.47M 488.05M 590.94M
Minority Interest Expense
32.18M 71.81M 103.18M 122.05M
Net Income
554.05M 336.66M 384.88M 468.89M
Net Income Growth
-24.54% -39.24% +14.32% +21.83%
Net Margin Growth
+8.51% +5.78% +6.77% +8.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
554.05M 336.66M 384.88M 468.89M
Preferred Dividends
- - - -
-
Net Income Available to Common
554.05M 336.66M 384.88M 468.89M
EPS (Basic)
0.2125 0.1261 0.1441 0.1772
EPS (Basic) Growth
-25.83% -40.66% +14.27% +22.97%
Basic Shares Outstanding
2.61B 2.67B 2.67B 2.65B
EPS (Diluted)
0.2125 0.1261 0.1441 0.1772
EPS (Diluted) Growth
-25.83% -40.66% +14.27% +22.97%
Diluted Shares Outstanding
2.61B 2.67B 2.67B 2.65B
EBITDA
826.85M 559.31M 802.90M 848.10M
EBITDA Growth
+26.60% -32.36% +43.55% +5.63%
EBITDA Margin
+12.71% +9.61% +14.12% +14.69%

Fosun International Ltd. in the News